Aguettant's Dzuveo, a sublingual sufentanil, receives EU approval and launch, targeting the hospital acute pain market.
Approval Scope and Product Value
The European Commission approved Dzuveo (sufentanil) on June 25, 2018, for the treatment of moderate to severe acute pain in adults. The marketed product, a 30-microgram sublingual tablet, activates the μ-opioid receptor in the central nervous system and is administered by healthcare professionals at intervals of at least one hour, up to a maximum of 48 hours. It is a hybrid medicine based on Sufenta (sufentanil), which has been approved in the EU since 1978. Its key operational value lies in its ability to be rapidly administered in operating rooms and emergency departments where intravenous access may be difficult.
Phase 3 Data and Safety
In a placebo-controlled phase 3 trial supporting the approval, the 12-hour Summed Pain Intensity Difference (SPID12) in 163 patients undergoing abdominal surgery was 26 for Dzuveo and 13 for placebo. In a study of 101 patients undergoing foot surgery, pain was reduced by approximately 6 points in the Dzuveo group, while it increased by approximately 7 points in the placebo group. Severe respiratory depression occurred in approximately 6 out of 1,000 patients, and nausea, vomiting, and fever were also common, limiting its use to healthcare facilities with monitoring equipment and resuscitation capabilities. Rather than efficacy differentiation, the convenience of reducing intravenous procedures and improving hospital operational efficiency is the central argument for its adoption.
Regulatory and Commercial History
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on April 26, 2018, and the current EU marketing authorization holder is Laboratoire Aguettant, a French unlisted pharmaceutical company. In the United States, Dsuvia (sufentanil), with the same active ingredient and dosage, received a 10-3 vote in favor at the FDA Advisory Committee meeting in October 2018 and was approved on November 2, 2018. The FDA imposed a Risk Evaluation and Mitigation Strategy (REMS), requiring administration by healthcare professionals in certified hospitals, surgical centers, and emergency departments for the treatment of severe acute pain. The developer, AcelRx Pharmaceuticals, changed its name to Talphera, Inc. (TLPH) in 2024, and Aguettant began European sales in the third quarter of 2022.
Market and Competitive Landscape
The European pain management market was valued at USD 23.09 billion in 2024, with non-steroidal anti-inflammatory drugs (NSAIDs) being the largest drug class. Dzuveo competes with intravenous morphine, fentanyl, and sufentanil, as well as multimodal analgesia combining acetaminophen, NSAIDs, and local/regional anesthesia. Zalviso (sufentanil) sublingual system, which has the same μ-opioid receptor agonist mechanism, had its EU marketing authorization withdrawn on August 5, 2022, for commercial reasons, reducing direct product competition. However, the availability of low-cost injectables and established opioid reduction guidelines mean that Dzuveo's sales growth will depend more on country-by-country reimbursement and formulary listing than on clinical efficacy.
Dzuveo is a hospital-use sublingual opioid that has completed phase 3 trials and is approved and marketed in the EU, with its operational efficiency in administration without intravenous access being a key differentiator in the USD 23.09 billion European pain management market. In the short term, Laboratoire Aguettant's securing of reimbursement in each country and formulary listing will determine sales conversion, while the low cost of morphine/fentanyl injectables and NSAID-based multimodal analgesia will act as a price barrier. Talphera, Inc. (TLPH) has secured an upfront payment of USD 2.9 million and milestone payments of USD 52.2 million, as well as a supply agreement and profit-sharing structure representing 35-45% of net sales. In the medium to long term, the withdrawal of Zalviso reduces direct competition, but the occurrence of severe respiratory depression in approximately 6 out of 1,000 patients and the limitation of administration to healthcare facilities require commercialization focused on the emergency and surgical niche markets rather than expansion to outpatient settings.
Source: EMA (ema)